Research Overview

The Ipamorelin / CJC-1295 (no DAC) Blend 10 mg (5mg+5mg) combines two complementary growth hormone secretagogues: Ipamorelin, a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R), and CJC-1295 (no DAC), a modified GHRH analog (Mod GRF 1-29). In experimental endocrinology, this dual-agonist blend is used as a tool compound to investigate GH/IGF-1 axis regulation, pituitary signaling and pulsatile growth hormone secretion patterns in in vitro and in vivo research models.

Primary Research Areas

• Growth hormone secretion dynamics: Laboratory models exploring synergistic GH release via concurrent activation of GHS-R by Ipamorelin and GHRH receptors by CJC-1295 (no DAC), including studies of GH pulse amplitude and frequency.
• Pituitary and hypothalamic signaling: Experiments evaluating downstream intracellular pathways in pituitary somatotrophs and hypothalamic circuits in response to combined ghrelin receptor and GHRH receptor stimulation.
• GH/IGF-1 axis modulation: Preclinical research assessing how the blend influences growth hormone and insulin-like growth factor 1 (IGF-1) patterns in controlled endocrine models, without implying any therapeutic or performance outcomes.
• Endocrine feedback and receptor interactions: Studies focused on feedback regulation, receptor desensitization and cross-talk between ghrelin, GHRH and somatostatin pathways under dual-secretagogue stimulation.
• Method development and assay calibration: Use of the Ipamorelin / CJC-1295 blend as a reference tool in assay development, bioanalytical method validation and mechanistic GH secretion research in vitro and in vivo.